Phaseline

Companies › ITM Solucin

ITM Solucin: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology, Gastroenterology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
177Lu-edotreotide PRRT
Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors
SSTR2, SSTR5Phase 3Neuroendocrine TumorsJun 2027
Lutetium Lu 177 Edotreotide
SSTR-targeting radiopharmaceutical therapy delivering Lu-177 radiation
SSTRPhase 1Somatostatin Receptor PositiveJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04919226177Lu-edotreotide PRRTPhase 3Neuroendocrine TumorsGastroenterologyJun 2027
NCT06441331Lutetium Lu 177 EdotreotidePhase 1Somatostatin Receptor PositiveOncologyJun 2028
NCT03049189177Lu-edotreotide PRRTPhase 3Neuroendocrine TumorsOncologyNov 2029

From the company's SEC filings

Complete response letters from FDA

Targets

SSTR2 (1) SSTR5 (1) SSTR (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology RECORDATI GROUP Debiopharm International Nanjing Chia-tai Tianqing Pharmaceutical Orano Med

Companies built like this

Advanced Accelerator Applications Orano Med RayzeBio Orca Biosystems Camurus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.